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Abstract  
In modern biomedicine the increasing need to develop experimental models to further our 
understanding of disease conditions and delineate innovative treatments has found in the 
zebrafish (Danio rerio) an experimental model, and indeed a valuable asset, to close the gap 
between in vitro and in vivo assays. Translation of ideas at a faster pace is vital in the field of 
neurodegeneration, with the attempt to slow or prevent the dramatic impact on society’s 
welfare being an essential priority. Our research group has pioneered the use of zebrafish to 
contribute to the quest for faster and improved understanding and treatment of 
neurodegeneration in concert with, and inspired by, many others who have primed the study of 
the zebrafish to understand and search for a cure for disorders of the nervous system. Aware of 
the many advantages this vertebrate model holds, here we present an update on the recent 
zebrafish models available to study neurodegeneration with the goal of stimulating further 
interest and increasing the number of diseases and applications for which they can be exploited. 
We shall do so by citing and commenting on recent break-throughs made possible via 
zebrafish, highlighting their benefits for the testing of therapeutics and dissecting of disease 
mechanisms.  
Keywords: neurodegenerative; Danio rerio; disease model; therapeutic testing; drug testing; 
mechanism 
 
 
 
 
 
 
 
 
 
 
 3 
Introduction 
In recent years the utility of zebrafish for disease modelling, mechanistic studies and 
therapeutic testing has been recognised by increasing numbers of researchers in many fields, 
but particularly in the field of neurodegeneration, due to the unique advantages of the zebrafish. 
These include the ability to generate and house large numbers of vertebrates relatively quickly, 
cheaply and in a small space, their transparency during development, the sophisticated genetic 
and phenotyping techniques available, their high level of biological relevance to humans, and 
the identification of developing zebrafish as a ‘replacement model’ to avoid the use of protected 
animals in experiments: this has been recently reviewed in detail elsewhere [1-4]. Of particular 
note is the use of zebrafish to identify the anti-arthritis drug leflunomide as a potential treatment 
for melanoma, which is now being tested in a Phase I/II clinical trial [3]. This demonstrates a 
sufficiently close relationship between zebrafish and human biology to support the continued 
use of zebrafish for compound testing and drug discovery. Indeed, many other studies hold the 
promise of leading to new drug treatments [1-3, 5].   
There are a huge number of neurodegenerative diseases, and zebrafish disease model 
generation has only scratched the surface, but recent technological innovations in genome 
editing promise to widen and strengthen inherited disease modelling in zebrafish [4]. Although 
gene editing has not yet been used to generate zebrafish models of neurodegenerative disease, 
models created using this new technology should be published in the near future. In this review 
we shall critically assess the most notable and recently published models, disease mechanisms 
and therapeutic testing utilising zebrafish (Table 1) and endeavour to stimulate further research 
in this important area. Although overlaps exist between epilepsy and neurodegenerative 
disease, we will refrain from reviewing zebrafish models of epilepsy in detail here as this 
disorder has been recently reviewed [1, 6], along with zebrafish models of mitochondrial 
disease [7, 8], metabolic disease [9] and neurological disorders [1, 10, 11]. 
 
Technological advances relating to zebrafish disease modelling 
A plethora of methods are now being used to generate disease models in zebrafish, dependent 
on the aetiology of the disease to be modelled. The zebrafish is highly amenable to 
manipulation and methods tend to be based on genetic alterations or chemical treatments and 
can include a combination of both (for extensive examples please refer to other reviews [1, 8-
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11]). The discovery of antisense morpholino oligonucleotides (MO) in 2000 revolutionised 
zebrafish research [12]. Injecting them into the embryo or tissue of interest results in dose-
dependent knock-down of the targeted gene, but with widespread use it has become apparent 
that they often have off-target effects and several methods are required to show these are not 
occurring. Mutants generated in mutagenesis screens have a similar issue in that a mutant line 
may harbour additional, unidentified mutations that could affect phenotypes. These can be 
limited by several generations of outcrossing. A more effective way to limit this is to use a 
mutagenesis method that results in few off-target mutations, as offered by recently published 
gene editing methods such as Zinc Finger Nucleases, TALENS and CRISPR/Cas9 [4]. Of 
these, CRISPR/Cas9 seems to be the most useful as it is easy to design reagents for any gene 
target, easy to implement, has a high rate of mutagenesis and a low level of off-target effects. 
Although initially developed to make mutant zebrafish, TALEN and CRISPR genome editing 
has now been used to knock-in genes [13], and further development of this technology 
promises to enable the replacement of zebrafish genes with their human counterparts, likely 
making the subsequent research using those strains more directly relevant to human disease. 
 
Zebrafish models of neurodegeneration 
Neurodegenerative disease has many different causes, ranging from toxic levels of metals to 
mitochondrial dysfunction or inherited mutations.  Here attention will be focused on the recent 
generation of novel inherited models and transient models. When a mutation causing a human 
disease is identified, modelling of that disease in zebrafish is often used to provide additional 
evidence supporting the causative gene. In other cases, zebrafish models have been made as a 
tool to perform research into finding treatments, often for incurable fatal diseases. As the 
embryo and larva is transparent and amenable to many more techniques than older zebrafish 
(e.g. genetic manipulation, transplantation, laser ablation), chemical treatments are cheaper on 
small fish, and results are achieved faster, it can be advantageous if a disease model has 
phenotypes at these early developmental stages. Some zebrafish disease models naturally have 
such an early onset and this reflects the human condition (e.g. Pontocerebellar hypoplasia [14, 
15]), others have an early onset even though the human disease onset appears to be later (e.g. 
CLN2 disease [16]), and yet others are created specifically to have a phenotype during 
development even though the human disease is adult onset (e.g. Parkinson’s Disease [17, 18]).  
In all cases, the degree to which the model reflects the biology of the human disease must be 
 5 
taken into account when interpreting the results, in addition to any other species-specific 
differences. 
 
Pontocerebellar hypoplasia 
Pontocerebellar hypoplasia is a group of inherited progressive neurodegenerative disorders 
with prenatal onset that manifests with microcephaly in infancy or early childhood and fatality 
in early life [19]. Children have profound intellectual disability and delayed or absent 
psychomotor skills, accompanied by lack of development of the pons and cerebellum. Several 
genes, including TSEN54, RARS and CLP1 have been identified as harbouring causative 
mutations with autosomal recessive inheritance [19]. The zebrafish has been used twice to 
support gene identification. In 2001, Kasher et al. used tsen54 antisense morpholino (MO) 
injection in zebrafish to attempt to mimic the human disease phenotype which is caused by 
mutation in TSEN54, a member of the tRNA splicing endonuclease complex (TSEN) (Table 
1) [14]. Morpholinos (MO) directed to the ATG or the exon 8 splice donor site gave similar 
phenotypes: an indistinct mid-hindbrain boundary (which develops into the cerebellum) and a 
greyness in the brain indicating cell death. The ATG MO was partially rescued by injection of 
human mRNA and this was taken as an indication that the human and zebrafish genes are not 
completely interchangeable in terms of function, but that the human gene can provide some of 
the zebrafish gene function. It is notoriously difficult to interpret this type of rescue experiment, 
as it remains possible that the phenotypes not rescued by the human mRNA are caused by off-
target morpholino toxicity. The authors included survival analysis from a mutant line to 
corroborate the morpholino results, but without demonstrating that the 24 hpf brain phenotype 
in the mutant is the same as that in the morphant, the question remains whether the cell death 
in the brain is attributable to loss of tsen54 or off-target morpholino toxicity. Such a study 
highlights the importance of using more than one method to model a disease in zebrafish and 
to validate the resulting disease phenotypes. One further way to provide corroborating evidence 
that the phenotype is specific to the gene knockdown is to knockdown other genes known to 
cause the same disease and compare phenotypes. Kasher et al. did this successfully when they 
showed essentially the same phenotype is caused by rars knockdown in zebrafish by 
morpholino injection (Table 1) [14]. 
The Kasher et al. study was followed by Schaffer et al, who determined that homozygous 
mutations in CLP1 can also cause pontocerebellar hypoplasia [15]. CLP1 is another member 
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of the tRNA splicing endonuclease complex (TSEN) and patient cells were shown to have 
reduced tRNA splicing activity suggesting a loss-of-function mutation. Schaffer et al. used 
R44X loss-of-function mutant zebrafish and demonstrated lack of clp1 mRNA expression, a 
reduction in expression of the otx2 midbrain marker and an increase in midbrain and hindbrain 
TUNEL stain which indicates cell death, both of which had an onset of about 48 hpf (Table 1) 
[15]. As predicted, abnormal spinal motor neurons were demonstrated in the clp1R44X mutants, 
using SV2 immunohistochemistry as a marker. Visible phenotypes included a curved body, 
small abnormal head and small eyes, and premature death by 5 dpf. These phenotypes were 
also seen in the second allele they examined, clpL35R (Table 1) [15], and have been 
demonstrated in other zebrafish models of pontocerebellar hypoplasia (tsen54 and rars 
morphants described above [14]) and other forms of neurodegeneration (e.g. CLN2 disease) 
[16]. The curved body and reduction in otx2 expression was partially rescued by injection of 
human CLP1 MRNA but not when it contained the mutation found in patients, showing that 
function was at least partially conserved and further corroborating the hypothesis that the 
zebrafish mutation is loss-of-function. Because the authors compared rescue using both normal 
and mutant human mRNA, it is possible to attribute the partial rescue to the human mRNA, 
but it remains unknown whether the lack of complete rescue is due to differences between the 
function of the human and zebrafish proteins or due to the global expression of the human 
protein causing additional phenotypes - background mutations are unlikely to contribute as 
several outcrosses were performed [15].  
Experiments where p53 was reduced using antisense morpholino injection into clpR44X embryos 
showed that otx2 expression was partially rescued and therefore p53 at least partly mediates 
the phenotype [15]. Given the role of p53 in stress-induced cell death, it was presumed, but not 
yet demonstrated that this was via a reduction in cell loss. One limitation in the publication was 
the absence of a hindbrain marker for their analyses, which would have been more relevant 
than a midbrain marker, given that pontocerebellar hypoplasia predominantly affects 
development and maintenance of structures that arise from the hindbrain. Even so, this series 
of experiments highlights very nicely how the zebrafish model can be used to support 
identification of human disease mutations and probe the underlying mechanisms. 
 
CLN2 disease 
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The recent publication by our group of a zebrafish model of the autosomal recessive lysosomal 
storage disorder CLN2 disease [16] illustrates that inherited diseases with an apparent onset in 
childhood can cause phenotypes during development of the zebrafish, perhaps making it more 
difficult to justify the direct relevance of the zebrafish model to the disease. CLN2 disease has 
an onset of around 2 years old and death usually occurs before adolescence [20], yet the 
zebrafish model has visible phenotypes from 2 dpf (smaller brain and eye, curved body and 
larger yolk) and dies by 7 dpf [16]. This early onset may be due to the precocious zebrafish 
development, the fact that it develops ex-ovo, or because TPP1 expression is upregulated 
earlier in the zebrafish than in humans. In spite of this, for all pathological and clinical signs 
examined to date, the zebrafish model has phenotypes equivalent to that of patients [16]. CLN2 
disease is caused by loss-of-function of the Tri-peptidyl peptidase 1 gene (Tpp1). We examined 
two tpp1 mutants and two tpp1 morphants in zebrafish and demonstrated that strong loss-of-
function (homozygous tpp1sa0011) resulted in early lethality whereas a weak allele (homozygous 
tpp1hu3587) gave similar phenotypes but at a lower frequency and with a later onset. Compound 
heterozygotes (tpp1sa0011 / tpp1hu3587) had an intermediate phenotype (Table 1) [16]. Although 
the compound heterozygotes may appear to be a better model than tpp1sa0011 mutants in terms 
of disease onset, they have a more variable phenotype so far more animals are required for 
experiments, and the later onset means that many of the advantages for drug discovery and 
manipulation that the embryo and larvae provide cannot be leveraged.   
Hence we focussed on the homozygous tpp1sa0011 mutants and were able to show many relevant 
phenotypes considered to be hallmarks of the disease apart from the reduced lifespan already 
mentioned: these include seizure-like movements followed by later lack of ability to move, 
nervous system cell death which was particularly evident in the retina, optic tectum, and 
cerebellum, reduced myelin, astrocytosis, enlarged lysosomes, and appropriate storage material 
[16]. As no one has yet demonstrated overt seizures or retinal degeneration in the mouse model 
[21], this zebrafish model is potentially more relevant to the disease than the mouse model. 
Compared to disease onset at 7 weeks in the mouse model [21], the embryonic onset and fast 
progression in the zebrafish model offers the potential to complete experiments much more 
quickly. 
We went on to demonstrate that axon path-finding and secondary proliferation were also 
impaired in tpp1sa0011 mutants [16] and this may be relevant to future therapeutic studies. For 
example, the lack of proliferation may be because cells need TPP1 to proliferate or because the 
degenerating brain does not support proliferation of cells. Mosaic analysis could be used to 
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distinguish between these two possibilities, as was demonstrated by mosaic analysis of the 
zebrafish flotte lotte mutant [22]. If it is shown that the degenerating brain does not support 
cell proliferation, this would have a large impact on when stem cell therapies would need to be 
given i.e. before the brain loses the ability to support proliferation. Our research also 
demonstrated that with careful analysis of locomotion at different stages, seizure-like 
locomotion can be identified even in a model of a disease with profound motor deficits (Figure 
1 A) [16]. This means that both locomotion phenotypes could be used for drug discovery, 
potentially enabling the identification of compounds or drugs that benefit specific aspects of 
the disease. 
 
Parkinson’s Disease and Dementia with Lewy Bodies 
-synuclein (aSyn) is one of the main intracellular storage materials both in Parkinson’s 
Disease (PD) and Dementia with Lewy Bodies (DLB), along with rare forms of PD caused by 
a variety of mutations in SNCA, the gene encoding  -synuclein (aSyn) [23]. Many cell and 
animal PD models have been generated using aSyn and studying these have shown that axon 
degeneration occurs before cell death, but the hypothesis that axon degeneration actually leads 
to cell death was not tested due to limitations of the available models. O’Donnell et al. used 
the distinct attributes of the developing zebrafish to answer this question. Their clever use of 
transgenes allowed them to transiently express aSyn in Rohon Beard sensory neurons and label 
both transgenic and normal Rohon Beard cells simultaneously with different fluorescent 
proteins (Table 1) [17], avoiding the use of tagged proteins that can cause aggregate formation. 
aSyn expression caused moderate levels of cell death by 3 dpf,  axon swelling was noted at 2 
dpf, and axon degeneration by 3 dpf, consistent with other models. Careful time-lapse analysis 
demonstrated that axon swellings always preceded cell death but axon degeneration 
(fragmentation) did not precede signs of cell death (Figure 1 B, C) [17]. Hence, the use of live 
fluorescent markers in the transparent zebrafish has provided evidence to support the 
hypothesis that axon swellings, not axon degeneration, precede cell death in aSyn 
overexpression models of PD. This experiment also highlights that the axonal compartment is 
more vulnerable than the cell body to aSyn toxicity. 
O’Donnell et al. went on to investigate the relationship between Wallerian degeneration and 
aSyn. They demonstrated that aSyn did not exacerbate Wallerian degeneration (induced by 
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transection of axons by a laser) but that this axotomy increased the amount of cell death caused 
by aSyn, suggesting that axon injury aggravates aSyn toxicity. However, expression of WldS, 
a protein that protects against Wallerian degeneration, did not reduce cell death caused by aSyn 
even though it had some positive effects in the axon compartment [17].  
In addition, the authors investigated mitochondrial transport using a live cox8:DsRed transgene 
and found that aSyn-expressing axons had a higher density of mitochondria, which were 
abnormally spherical and swollen, suggesting respiratory chain dysfunction. Timelapse movies 
showed reduced mitochondrial motility, especially in the anterograde direction, at 2 dpf [17] 
suggesting that it might contribute to cell death and axonopathy. To test this, they expressed 
PGC-1, a transcriptional co-activator that has varied roles in mitochondrial biogenesis and 
ROS detoxification [18], in the same cells as aSyn and found that both cell death and 
axonopathy were rescued to normal levels [17], which is supported by experiments in mice 
where PGC-1 protects dopaminergic neurons in a chemical model of PD. Although it is still 
very unclear how PGC-1 is protecting against cell death in this system, this research 
corroborates PGC-1a as a promising target and illustrates the use of genetic manipulation in 
zebrafish to find therapeutic targets. 
 
Amyotrophic lateral sclerosis 
The identification and development of treatments for neurodegenerative diseases is a major 
reason behind developing zebrafish models. As mentioned before, other diseases are beginning 
to benefit from this approach. ALS has a complex aetiology with some families identified with 
ALS-causing mutations in TAR DNA Binding Protein 43 (TDP-43) [24]. To identify 
compounds that have potential for treating ALS, Vaccaro et al. used zebrafish (Table 1) and 
the nematode (C. elegans) expressing mutant TDP-43 (mTDP-43), via transient injection and 
as an integrated transgenic respectively, to test three neuroprotective agents: riluzole, lithium 
and methylene blue [25]. In the zebrafish mTDP-43 model, the touch evoked escape response, 
a read out for motor function, was almost absent, motor axons were shorter and abnormally 
branched (as demonstrated by znp-1 immunohistochemistry), and oxidative stress was 
increased (as demonstrated by dihydrofluorescein diacetate fluorescence in live zebrafish). 
Vaccaro et al. found that methylene blue improved relevant phenotypes in both models, likely 
through reducing ER stress [25]. This was the first time that in vivo phenotypes had been used 
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for chemical screening for ALS. Subsequently, Vaccaro et al. determined that the ER is the 
most likely source of the stress in the C. elegans model and therefore selected other chemicals 
thought to act by reducing ER stress (and the ER unfolded protein response) and treated the 
nematode and fish mTDP-43 models with these [26]. Three agents (salubrinal, guanabenz and 
phenazine) were found to rescue paralysis, neurodegeneration and oxidative stress, albeit 
through different parts of the ER stress pathway (Figure 1 D) [26]. These results show that the 
ER unfolded protein response is an important target for therapeutic development, and this has 
recently been borne out by guanabenz treatment in G93A mtSOD1 transgenic mice, which 
results in a delay in onset, elongation of the early disease phase, and lengthened survival [27, 
28]. This zebrafish research has therefore contributed directly to the identification of 
guanabenz, an approved drug for hypertension, as a priority drug to pursue for the treatment of 
ALS. 
 
Conclusions 
The examples in this review demonstrate that zebrafish has clearly some unique advantages 
over other model organisms for modelling neurodegeneration. However, these advantages can 
also be their weakness: for example an earlier onset in zebrafish than in humans causes us to 
question their validity but this attribute also means that the model could be used for time-lapse 
imaging or drug discovery, with far more experiments that can be done more quickly and 
cheaply than in mammals.  
With the advent of genome editing techniques in zebrafish, the frequency with which new 
models of monogenetic inherited disease are published is predicted to increase significantly as 
these will be the most straightforward to model and possibly the most easily equated to human 
disease.  Many rare neurodegenerative disease are devastating, they frequently cause 
neurodegeneration in children, and their study is mainly supported by small charities. Hence, 
study of these diseases could gain most by exploiting the advantages of the zebrafish model. 
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Figure legends 
Figure 1. Developing zebrafish offer significant advantages for disease modelling and 
drug discovery.  
(A) Motor deficits in the tpp1sa0011 mutant zebrafish at 96 hpf (above) are preceded by seizure-
like excessive locomotion at 72 hpf (below). Tracks in a 20 minute period are shown in 
blue/red. Adapted from Mahmood, F., et al., A zebrafish model of CLN2 disease is deficient in 
tripeptidyl peptidase 1 and displays progressive neurodegeneration accompanied by a 
reduction in proliferation. Brain, 2013. 136(Pt 5): p. 1488-1507, with permission from Oxford 
University Press [16].  
(B, C) Time-lapse imaging of neurodegeneration in aSyn-expressing neurons. Cells were 
imaged every 20 minutes beginning 54 hours post-fertilization (hpf). Axons from at least 11 
embryos from each group were transected; representative images from aSyn-expressing 
animals are shown. Time stamps in images are relative to the start of the imaging period. 
Axonal varicosities were observed (white arrowheads) several hours before cell death. White 
arrows point to morphological changes indicative of cell death. Inset represents cell body 
magnified 2×. Asterisk in B indicates separation of the axon from the cell body. Axonal 
fragmentation (blue arrowheads) usually did not occur before cell death, and was not 
stereotyped: it did not occur synchronously along the length of the axon, nor in a retrograde 
direction (yellow arrows point to distal portions of the axon that are still intact). Scale bars: 
50 μm. Reproduced under the Creative Commons Attribution Licence from O’Donnell K C et 
al. Dis. Model. Mech. 2014; 7: 571-582 [17].  
(D) Escape response in mTDP-43 expressing zebrafish and with treatment of salubrinal (Sal), 
guanabenz (Gua) and phenazine (Phe). Reprinted from Vaccaro, A., et al., Pharmacological 
reduction of ER stress protects against TDP-43 neuronal toxicity in vivo. Neurobiology of 
Disease, 2013. 55: p. 64-75 [26], with permission from Elsevier. 
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Table 1. Summary of the key findings attained from the zebrafish models of neurodegenerative 
disease reviewed in this article. 
Human 
disease  
onset 
Disease Type of zebrafish 
model 
Outcome summary Ref. 
Prenatal Pontocerebellar 
hypoplasia 
tsen54 morphant (ATG) Brain hypoplasia and loss of structural 
definition inside the brain including cerebellum 
at 24 hpf. Partially rescued by co-injecting 
human TSEN54 mRNA 
[14] 
  tsen54 morphant 
(exon 8 splice 
donor site) 
Brain hypoplasia and reduced structural 
definition inside the brain including cerebellum 
at 24 hpf. 
[14] 
  tsen54R228X/R228X mutant Lethal by 9 dpf (with 62% tsen54R228X-/+ 
heterozygotes surviving to 21 dpf). 
[14] 
  rars2 morphant (ATG) Brain hypoplasia and reduced structural 
definition inside the brain including cerebellum 
at 24 hpf. Partially rescued by co-injecting 
human rars2 mRNA. 
[14] 
  rars2 morphant (exon 6 
splice 
donor site) 
Brain hypoplasia and reduced structural 
definition inside the brain including cerebellum 
at 24 hpf. 
[14] 
  clp1R44X mutant Abnormal head shape and curved tail. Small 
eyes. Abnormal swimming behavior. Premature 
death by 5 dpf. The average curve height is 
partially rescued by human CLP1 mRNA 
[15] 
  clp1L35R mutant Similar uniform lethality by 5 dpf than 
CLP1R44X 
[15] 
Juvenile CLN2 Disease tpp1sa0011/sa0011 
 mutants 
Curved body, small eyes and head, large yolk at 
48hpf. No detectable jaw, pericardial oedema at 
72hpf. Lethality by 7dpf. Seizure-like 
movements followed by later lack of ability to 
move. Nervous system cell death, lack of 
proliferation, reduced axons. 
[16] 
  tpp1hu3587/hu3587 
mutant 
Similar phenotypes to tpp1sa0011 but at a lower 
frequency and with a later onset. Some are 
adult viable. 
[16] 
  tpp1sa0011/hu3587 
mutant 
Similar phenotypes to tpp1sa0011 but with a later 
onset of 72hpf 
 
  tpp1 morphant 
(exon 2 splice acceptor 
site) 
Abnormal phenotype beginning 
around 48 h post fertilization including 
increasingly smaller eyes 
and head, curvature within the body axis, a 
reduced jaw 
[16] 
  tpp1 morphant 
(ATG) 
Abnormal phenotype beginning 
around 48 h post fertilization including 
increasingly smaller eyes 
and head, curvature within the body axis, a 
reduced jaw 
[16] 
Adult Parkinson’s 
Disease and 
Dementia with 
Lewy Bodies 
Transgenic aSyn-2A-
GFP transiently 
expressed in Rohon 
Beard neurons 
Neuron death and axonopathy between 2-3 dpf. 
Aberrations in mitochondrial morphology, 
density and motility at 2 dpf 
[17] 
 Amyotrophic 
lateral sclerosis 
mTDP-43[G48C] mRNA 
injection 
Abnormally shortened and branched motor 
neuron axonal processes at 2 dpf. Motor deficit. 
Rescued by methylene blue and other 
compounds reducing ER stress. 
[25, 26] 
  mFUS[R21H] mRNA 
injection 
Abnormally shortened and branched motor 
neuron axonal processes at 2 dpf. Motor deficit. 
Rescued by methylene blue. 
[25] 
 
 
